Q1 FY2025 · ended Mar 31, 2025 · Revenue $2.57M, +76.6% YoY · Filed Aug 14, 2026
Tvardi Therapeutics, Inc. (TVRD) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $15.8 million in cash and investments and $145,000 in total debt.
Revenue
$2.57M
+76.6% vs prior quarter
Net income
$-6.46M
-255.0% vs year-ago quarter
Operating cash flow
$-9.23M
-57.3% vs year-ago quarter
Free cash flow
$-4.83M
+27.4% vs prior quarter
EPS
$-0.69
+31.0% vs year-ago quarter
Dividend per share
$0.00
Shares outstanding
13.34M
+42.2% vs year-ago quarter
Net cash
$15.62M
Q2 FY2026
Operating margin
-36.9%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TVRD (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Sugar Land, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1346830
- Former names
- Cara Therapeutics, Inc. (until Apr 11, 2025); Cara Therapeutics Inc (until Jul 21, 2010)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$6.6M | -$7.1M | -$7.6M | -$5.9M | -$8.9M |
| Net income | -$6.5M | -$6.8M | -$7.3M | -$5.5M | $4.2M |
| Diluted EPS | -$0.69 | -$0.73 | -$0.78 | -$0.59 | -$1.00 |
| Operating cash flow | -$9.2M | -$5.9M | -$5.7M | -$4.3M | -$5.9M |
| Total assets | $17.5M | $25.8M | $32.1M | $39.0M | $43.8M |
| Total liabilities | $9.1M | $11.3M | $11.1M | $11.2M | $10.8M |
| Stockholders' equity | $8.4M | $14.5M | $20.9M | $27.9M | $32.9M |
| Cash and investments | $15.8M | $25.0M | $30.8M | $36.5M | $41.0M |
| Total debt | $145,000 | $174,000 | $201,000 | $228,000 | $254,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 14, 2026 | Aug 14, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 30, 2026 | Jul 30, 2026 |
| 8-K |
Current report
Other events
|
Jul 17, 2026 | Jul 17, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 7, 2026 | Jul 7, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 11, 2026 | Jun 9, 2026 |
All 809 Tvardi Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.